Terms: = Bone cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
510 results:
1. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract] [Full Text] [Related]
2. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
[TBL] [Abstract] [Full Text] [Related]
3. bone Morphogenic Proteins in Pediatric Diffuse Midline Gliomas: How to Make New Out of Old?
Berthelot C; Huchedé P; Bertrand-Chapel A; Beuriat PA; Leblond P; Castets M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542334
[TBL] [Abstract] [Full Text] [Related]
4. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1.
Adachi Y; Noguchi R; Yoshimatsu Y; Sin Y; Osaki J; Ono T; Iwata S; Akiyama T; Tsuchiya R; Toda Y; Ishihara S; Ogura K; Kobayashi E; Kojima N; Yoshida A; Yokoo H; Kawai A; Kondo T
Hum Cell; 2024 May; 37(3):874-885. PubMed ID: 38466561
[TBL] [Abstract] [Full Text] [Related]
5. A 50-Year-Old Man Presenting with Multiple bone Lesions and a Diagnosis of Phosphaturic Mesenchymal Tumor of the Femur.
Ren D; Wei K; Ifegwu I
Am J Case Rep; 2024 Feb; 25():e942810. PubMed ID: 38361352
[TBL] [Abstract] [Full Text] [Related]
6. Deposition of onco-histone H3.3-G34W leads to DNA repair deficiency and activates cGAS/STING-mediated immune responses.
Mancarella D; Ellinghaus H; Sigismondo G; Veselinov O; Kühn A; Goyal A; Hartmann M; Fellenberg J; Krijgsveld J; Plass C; Popanda O; Schmezer P; Bakr A
Int J Cancer; 2024 Jun; 154(12):2106-2120. PubMed ID: 38353495
[TBL] [Abstract] [Full Text] [Related]
7. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Stepien N; Mayr L; Schmook MT; Raimann A; Dorfer C; Peyrl A; Azizi AA; Schramm K; Haberler C; Gojo J
Pediatr Blood Cancer; 2024 Mar; 71(3):e30836. PubMed ID: 38177074
[TBL] [Abstract] [Full Text] [Related]
8. Myeloid and lymphoid neoplasm with novel complex translocation: unusual case report with T-lymphoblastic lymphoma, myeloid hyperplasia, eosinophilia, basophilia, and t(1;8;10)( (p31;q24;q11.2).
Aljabry MS
J Hematop; 2023 Mar; 16(1):27-31. PubMed ID: 38175368
[TBL] [Abstract] [Full Text] [Related]
9. Giant Cell Tumor of the Acromion: Case Report and Literature Review.
Sano J; Chijiiwa Y; Nishio J
In Vivo; 2024; 38(1):506-510. PubMed ID: 38148094
[TBL] [Abstract] [Full Text] [Related]
10. Proteomic profiling of serum exosomes reveals acute phase response and promotion of inflammatory and platelet activation pathways in patients with heat stroke.
Li Y; Li H; Ma W; Maegele M; Tang Y; Gu Z
PeerJ; 2023; 11():e16590. PubMed ID: 38107577
[No Abstract] [Full Text] [Related]
11. FGF2 drives osteosarcoma metastasis through activating fgfr1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
12. Spatial proteomics identifies a spectrum of immune dysregulation in acquired bone marrow failure syndromes.
Koldej RM; Prabahran A; Tan CW; Ludford-Menting M; Morgan H; Holzwart N; Davis MJ; Ritchie DS
Front Immunol; 2023; 14():1213560. PubMed ID: 37818364
[TBL] [Abstract] [Full Text] [Related]
13. Klotho Overexpression Is Frequently Associated With Upstream Rearrangements in Fusion-Negative Phosphaturic Mesenchymal Tumors of bone and Sinonasal Tract.
Lee JC; Hsieh TH; Kao YC; Tsai CF; Huang HY; Shih CY; Song HL; Oda Y; Chih-Hsueh Chen P; Pan CC; Sittampalam K; Petersson F; Konishi E; Chiu WY; Chen CF; Carpenter TO; Lu TP; Chang CD; Huang SC; Folpe AL
Mod Pathol; 2023 Dec; 36(12):100336. PubMed ID: 37742927
[TBL] [Abstract] [Full Text] [Related]
14. Periosteal chondroblastoma of the femoral neck: two cases and a review of the literature.
Guillois C; Yang S; Biau D; Feydy A; Larousserie F
Skeletal Radiol; 2024 May; 53(5):1003-1009. PubMed ID: 37733062
[TBL] [Abstract] [Full Text] [Related]
15. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract] [Full Text] [Related]
16. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S; Schuler M; Iyer G; Witt O; Doi T; Qin S; Tabernero J; Reardon DA; Massard C; Minchom A; Lugowska I; Carranza O; Arnold D; Gutierrez M; Winter H; Stuyckens K; Crow L; Najmi S; Hammond C; Thomas S; Santiago-Walker A; Triantos S; Sweiti H; Loriot Y;
Lancet Oncol; 2023 Aug; 24(8):925-935. PubMed ID: 37541273
[TBL] [Abstract] [Full Text] [Related]
17. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.
Bitler BG; Bailey CA; Yamamoto TM; McMellen A; Kim H; Watson ZL
Mol Carcinog; 2023 Nov; 62(11):1717-1730. PubMed ID: 37493106
[TBL] [Abstract] [Full Text] [Related]
18. Myeloid/Lymphoid Neoplasm with fgfr1 Rearrangement Presenting with Polycythemia Vera and T-cell Acute Lymphoblastic Leukemia.
Marinelli LM; Romain JT; Ehman W; Ortega V; Velagaleti G; Gibbons TF; Nazario-Toole A; Holmes AR
Cancer Genet; 2023 Aug; 276-277():43-47. PubMed ID: 37480761
[TBL] [Abstract] [Full Text] [Related]
19. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract] [Full Text] [Related]
20. Utility of immunohistochemical expression of H3.3K36M and DOG1 in the diagnosis of chondroblastomas: An experience from a tertiary cancer referral center.
Rekhi B; Dave V; Butle A; Dutt A
Ann Diagn Pathol; 2023 Oct; 66():152174. PubMed ID: 37356274
[TBL] [Abstract] [Full Text] [Related]
[Next]
